Cardiologist Eric Topol takes a critical look at the peptide boom, noting that beyond GLP-1 receptor agonists — which have robust outcome data — most other peptides in the wellness market still lack proven health-outcome benefits. A useful framing for separating the evidence-backed class from the hype.